290,700 Shares in Bioventus Inc. $BVS Bought by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC bought a new position in shares of Bioventus Inc. (NYSE:BVS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 290,700 shares of the company’s stock, valued at approximately $1,924,000.

A number of other hedge funds have also bought and sold shares of BVS. Nuveen LLC bought a new position in Bioventus during the first quarter worth $4,700,000. Driehaus Capital Management LLC raised its stake in Bioventus by 29.1% during the first quarter. Driehaus Capital Management LLC now owns 1,445,257 shares of the company’s stock worth $13,224,000 after buying an additional 325,402 shares during the last quarter. Invesco Ltd. raised its stake in Bioventus by 1,303.6% during the first quarter. Invesco Ltd. now owns 268,028 shares of the company’s stock worth $2,452,000 after buying an additional 248,932 shares during the last quarter. Royce & Associates LP raised its stake in Bioventus by 21.8% during the first quarter. Royce & Associates LP now owns 892,216 shares of the company’s stock worth $8,164,000 after buying an additional 159,980 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Bioventus by 18.0% during the first quarter. American Century Companies Inc. now owns 1,044,212 shares of the company’s stock worth $9,555,000 after buying an additional 159,539 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

Bioventus Trading Down 3.3%

NYSE:BVS opened at $6.79 on Tuesday. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The stock has a market capitalization of $561.39 million, a price-to-earnings ratio of -11.13 and a beta of 0.81. The firm has a fifty day simple moving average of $7.02 and a two-hundred day simple moving average of $7.12. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $14.38.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald initiated coverage on shares of Bioventus in a report on Monday, July 7th. They issued an “overweight” rating and a $12.00 price target for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Bioventus has an average rating of “Moderate Buy” and a consensus price target of $13.75.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.